Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Hookipa Pharma Inc Market Cap
Based on ratings from 4 stock analysts, the Hookipa Pharma Inc stock price is expected to increase by 1507.88% in 12 months. This is calculated by using the average 12-month stock price forecast for Hookipa Pharma Inc. The lowest target is $7 and the highest is $60. Please note analyst price targets are not guaranteed and could be missed completely.
Hookipa Pharma Inc has a total of 4 Wall St Analyst ratings. There are 4 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Hookipa Pharma Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of HOOK.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Roy Buchanan JMP Securities | Market Outperform | $7 | Maintains | Nov 21, 2024 |
| Brian Abrahams RBC Capital | Outperform | $48 | Maintains | Nov 15, 2024 |
| Roy Buchanan JMP Securities | Market Outperform | $24 | Maintains | Aug 9, 2024 |
| Jason Butler JMP Securities | Market Outperform | $23 | Maintains | Jul 26, 2024 |
| Arthur He HC Wainwright & Co. | Buy | $6 | Maintains | Jun 5, 2024 |
| Brian Abrahams RBC Capital | Outperform | $5 | Reiterates | May 21, 2024 |
| Arthur He HC Wainwright & Co. | Buy | $5 | Maintains | Apr 26, 2024 |
| Brian Abrahams RBC Capital | Outperform | $5 | Reiterates | Mar 25, 2024 |
| Arthur He HC Wainwright & Co. | Buy | $6.5 | Reiterates | Mar 25, 2024 |
| Brian Abrahams RBC Capital | Outperform | $5 | Maintains | Jan 30, 2024 |
| Brian Abrahams RBC Capital | Outperform | $7 | Reiterates | Sep 27, 2023 |
| Asthika Goonewardene Truist Securities | Buy | $4 | Reiterates | Sep 6, 2023 |
| Arthur He HC Wainwright & Co. | Buy | $6.5 | Maintains | Aug 11, 2023 |
| Brian Abrahams RBC Capital | Outperform | $7 | Reiterates | Jun 30, 2023 |
Morgan Stanley | Equal-Weight | Maintains | Jun 5, 2023 | |
| Arthur He HC Wainwright & Co. | Buy | $8 | Reiterates | May 12, 2023 |
| Asthika Goonewardene Truist Securities | Buy | $4 | Maintains | Mar 20, 2023 |
| Arthur He HC Wainwright & Co. | Buy | $8 | Reiterates | Mar 16, 2023 |
| Alec Stranahan B of A Securities | Underperform | $0.5 | Downgrade | Dec 2, 2022 |
| Brian Abrahams RBC Capital | Outperform | $7 | Maintains | Nov 15, 2022 |
When did it IPO
2019
Staff Count
151
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Malte Peters M.D.
Market Cap
$29.1M
In 2023, HOOK generated $20.1M in revenue, which was a increase of 41.27% from the previous year. This can be seen as a signal that HOOK's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 11 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A Phase 2 trial of eseba-vec/pembrolizumab shows a 52% overall response rate in PD-L1 CPS>20 patients, with promising progression-free and overall survival data and good safety profile.
Why It Matters - Positive trial results for eseba-vec/pembrolizumab suggest strong efficacy and safety, potentially increasing the stock value of the involved biotech company and attracting more investment interest.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A study led by Dr. Winston Wong and Dr. Alan Ho at Memorial Sloan Kettering focuses on head and neck oncology, indicating ongoing research in this medical field.
Why It Matters - Collaboration with renowned institutions like Memorial Sloan Kettering can enhance credibility and drive innovations in oncology, potentially impacting stock performance for related healthcare companies.
Thu, 31 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Dr. Alan Ho from Memorial Sloan Kettering Cancer Center will present a poster at the Society of Immunotherapy of Cancer (SITC) on November 9, 2024.
Why It Matters - The presentation by Dr. Alan Ho on immunotherapy may indicate potential advancements in cancer treatment, impacting biotech stock valuations and investor interest in related companies.
Tue, 24 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A preclinical proof-of-concept package will be presented at the Industry Summit on RAS from September 24-26, 2024, which may impact related investment opportunities.
Why It Matters - Upcoming presentation on preclinical proof-of-concept for RAS could indicate potential breakthroughs, impacting stock prices and investment decisions in biotech sectors focused on cancer therapies.
Tue, 17 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Kaskela Law LLC is investigating HOOKIPA Pharma Inc. (NASDAQ: HOOK) for potential securities law violations as shares have plummeted over 50% since May 2024, from over $10 to below $5.
Why It Matters - The investigation into HOOKIPA Pharma signifies potential legal issues, which could further depress share prices and impact investor confidence and returns.
Mon, 02 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Analysts' price targets for HOOKIPA Pharma (HOOK) suggest a 622.8% upside. There is strong agreement on raised earnings estimates, indicating potential stock growth.
Why It Matters - Analysts' price targets suggest significant potential upside for HOOK, indicating positive sentiment and possible future stock appreciation, despite historical target accuracy concerns.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
